Published October 12, 2009 | Version v1
Journal article

Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells

Description

The combination therapy of interferon (IFN)-alpha and 5-fluorouracil (5-FU) improved the prognosis of the patients with hepatocellular carcinoma (HCC). To determine the molecular mechanisms of the anti-tumor and anti-angiogenic effects, we examined the direct anti-proliferative effects on human umbilical vein endothelial cells (HUVEC) and indirect effects by regulating secretion of angiogenic factors from HCC cells. The direct effects on HUVEC were examined by TUNEL, Annexin-V assays and cell cycles analysis. For analysis of the indirect effects, the apoptosis induced by the conditioned medium from HCC cell treated by IFN-alpha/5-FU and expression of angiogenic factors was examined. IFN-alpha and 5-FU alone had anti-proliferative properties on HUVEC and their combination significantly inhibited the growth (compared with control, 5-FU or IFN alone). TUNEL and Annexin-V assays showed no apoptosis. Cell cycle analysis revealed that IFN-alpha and 5-FU delayed cell cycle progression in HUVEC with S-phase accumulation. The conditioned medium from HuH-7 cells after treatment with IFN/5-FU significantly inhibited HUVEC growth and induced apoptosis, and contained high levels of angiopoietin (Ang)-1 and low levels of vascular endothelial growth factor (VEGF) and Ang-2. Knockdown of Ang-1 in HuH-7 cells abrogated the anti-proliferative effects on HUVEC while knockdown of Ang-2 partially rescue the cells. These results suggested that IFN-alpha and 5-FU had direct growth inhibitory effects on endothelial cells, as well as anti-angiogenic effects through regulation of angiogenic factors released from HCC cells. Modulation of VEGF and Angs secretion by IFN-alpha and 5-FU may contribute to their anti-angiogenic and anti-tumor effects on HCC

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-9-361; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767355

Additional details

Publishing Information

Journal Title
BMC Cancer (Online)
Journal Volume
9
Journal Page Range
p. 361
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46093040
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
APOPTOSIS; BUILDUP; CARCINOMAS; CELL CYCLE; GROWTH; INTERFERON; MODULATION; PATIENTS; THERAPY; TUMOR CELLS; VEINS
Descriptors DEC
ANIMAL CELLS; BLOOD VESSELS; BODY; CARDIOVASCULAR SYSTEM; DISEASES; GROWTH FACTORS; LYMPHOKINES; MEDICINE; MITOGENS; NEOPLASMS; ORGANIC COMPOUNDS; ORGANS; PROTEINS

Optional Information

Copyright
Copyright (c)2009 Wada et al
Notes
PMCID: PMC2767355; PUBLISHER-ID: 1471-2407-9-361; PMID: 19821965; OAI: oai:pubmedcentral.nih.gov:2767355; licensee BioMed Central Ltd.